pemetrexed · Alimta

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
US
  • Mesothelioma ALIMTA is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
Product first approved 2004Outside this platform's coverageFDA label
EU
  • Alimta with cisplatin first-line for locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous histology; also mesothelioma
Product first approved 2004EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (129)
Non-Small Cell Lung Cancer
NCT06096844 · National Cancer Institute (NCI)
2024-07-19 – 2039-04-01 · Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT07877584 · German Cancer Research Center
2026-11-30 – 2033-11-30 · Non-Small Cell Lung Cancer
What this study did
NCT07897188 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
2026-10-30 – 2032-11-20 · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
What this study did
NCT07943325 · Goethe University
2027-02 – 2032-02 · Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT07822542 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2026-10-31 – 2031-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07829549 · RemeGen Co., Ltd.
2026-10-10 – 2031-08 · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
What this study did
NCT06627647 · AstraZeneca
2024-11-27 – 2030-11-18 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT06632327 · Alliance for Clinical Trials in Oncology
2024-12-11 – 2030-04-30 · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT04267848 · National Cancer Institute (NCI)
2020-06-16 – 2030-01-31 · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT07154368 · Guangzhou JOYO Pharma Co., Ltd
2025-09-23 – 2029-12-31 · Non Small Cell Lung Cancer
What this study did
NCT07524257 · ImmunityBio, Inc.
2026-05-29 – 2029-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
What this study did
NCT04380636 · Merck Sharp & Dohme LLC
2020-07-06 – 2029-07-06 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT04351555 · AstraZeneca
2020-12-16 – 2029-06-13 · Non-Small Cell Lung Cancer
What this study did
NCT05502237 · Gilead Sciences
2022-10-12 – 2029-01 · Non-small Cell Lung Cancer
What this study did
NCT04092283 · National Cancer Institute (NCI)
2020-04-29 – 2028-12-31 · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT05722015 · Merck Sharp & Dohme LLC
2023-02-14 – 2028-05-22 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT07383116 · Shanghai Huaota Biopharmaceutical Co., Ltd.
2026-01-15 – 2028-04-10 · Non Squamous Non-small Cell Lung Cancer
What this study did
NCT04585490 · Stanford University
2021-08-25 – 2028-04 · Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
What this study did
NCT04695925 · Li Zhang, MD
2021-03-29 – 2027-12-30 · Non-small Cell Carcinoma, EGFR Gene Mutation
What this study did
NCT03164616 · AstraZeneca
2017-06-01 – 2027-11-15 · Non Small Cell Lung Cancer NSCLC
What this study did
NCT05984277 · AstraZeneca
2023-10-24 – 2027-11-12 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT06704620 · Tianjin Medical University Cancer Institute and Hospital
2024-12 – 2027-11 · Advanced and Metastatic NSCLC
What this study did
NCT04035486 · AstraZeneca
2019-07-02 – 2027-09-30 · Non-Small Cell Lung Cancer
What this study did
NCT03793179 · National Cancer Institute (NCI)
2019-04-05 – 2027-09-30 · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT06687369 · mAbxience Research S.L.
2024-12-30 – 2027-09 · Non Squamous Non Small Cell Lung Cancer
What this study did
NCT05059522 · Pfizer
2021-09-29 – 2026-12-31 · Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
What this study did
NCT06505837 · Shanghai Junshi Bioscience Co., Ltd.
2024-07-11 – 2026-12-30 · Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
What this study did
NCT06754644 · Qilu Pharmaceutical Co., Ltd.
2025-01-15 – 2026-12 · NSCLC
What this study did
NCT05990127 · Akeso
2023-11-14 – 2026-11-28 · Locally Advanced or Metastatic NSCLC
What this study did
NCT02486718 · Hoffmann-La Roche
2015-10-31 – 2026-08-26 · Non-Small Cell Lung Cancer
What this study did
NCT06624059 · Hoffmann-La Roche
2024-11-18 – 2026-07-31 · Non-Small Cell Lung Cancer
What this study did
NCT04205812 · Incyte Corporation
2020-09-11 – 2026-05-28 · Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
What this study did
NCT03976323 · Merck Sharp & Dohme LLC
2019-06-28 – 2026-01-30 · Carcinoma, Nonsquamous Non-small-cell Lung
What this study did
NCT03520686 · ImmunityBio, Inc.
2018-05-18 – 2025-10-13 · Non Small Cell Lung Cancer
What this study did
NCT04619433 · Jiangsu HengRui Medicine Co., Ltd.
2021-02-01 – 2025-08-16 · Non-squamous Non-small-cell Lung Cancer
What this study did
NCT03992885 · Tianjin Medical University Cancer Institute and Hospital
2019-07-01 – 2025-08-01 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT06280196 · Bio-Thera Solutions
2024-07-19 – 2025-07-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00324805 · National Cancer Institute (NCI)
2007-07-19 – 2025-01-31 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
What this study did
Phase 2/3 (19)
Non-Small Cell Lung Cancer
NCT07865910 · Shanghai Henlius Biotech
2026-11-30 – 2031-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT05800015 · Regeneron Pharmaceuticals
2023-08-08 – 2031-12-23 · Non-small Cell Lung Cancer
What this study did
NCT06712316 · BioNTech SE
2025-01-07 – 2031-12 · Non-small Cell Lung Cancer
What this study did
NCT06335355 · Shanghai Shengdi Pharmaceutical Co., Ltd
2024-03 – 2030-10 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT07662395 · Sinocelltech Ltd.
2026-05-09 – 2030-01-24 · Double Blind
What this study did
NCT05255302 · Intergroupe Francophone de Cancerologie Thoracique
2022-05-02 – 2029-06-01 · Metastatic NSCLC
What this study did
NCT07131319 · Second Affiliated Hospital of Nanchang University
2025-04-21 – 2028-12-31 · Non-Small Cell Lung Cancer
What this study did
NCT03178552 · Hoffmann-La Roche
2017-09-22 – 2027-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT03380468 · Fudan University
2018-01-01 – 2025-12-31 · Lung Neoplasms
What this study did
NCT04750083 · Taizhou Hanzhong biomedical co. LTD
2020-09-25 – 2023-09-25 · Nonsquamous Non-small Cell Lung Cancer
What this study did
NCT01774578 · NewLink Genetics Corporation
2013-02 – 2016-06-18 · Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
What this study did
NCT01769066 · Fudan University
2009-12 – 2014-02 · NSCLC
What this study did
Other / comorbidity
NCT02784171 · Canadian Cancer Trials Group
2016-11-11 – 2024-10-11 · Mesothelioma
What this study did
NCT02709512 · Polaris Group
2017-08-01 – 2022-08-15 · Mesothelioma
What this study did
NCT00651456 · Intergroupe Francophone de Cancerologie Thoracique
2008-02 – 2016-09 · Mesothelioma
What this study did
Phase 2 (480)
Non-Small Cell Lung Cancer
NCT07720167 · Medical University of South Carolina
2027-02-01 – 2036-08-01 · Non-Small Cell Lung Cancer
What this study did
NCT07309952 · Yang Hong
2025-12-31 – 2032-10-31 · Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
What this study did
NCT07234877 · European Organisation for Research and Treatment of Cancer - EORTC
2026-11 – 2032-04 · Non Small Cell Lung Cancer
What this study did
NCT06788912 · Merck Sharp & Dohme LLC
2025-03-20 – 2032-02-06 · Lung Neoplasm Malignant
What this study did
NCT07845916 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-10-10 – 2031-12-31 · Non-Small Cell Lung Cancer
What this study did
NCT07890493 · Canadian Cancer Trials Group
2026-12-31 – 2031-06-30 · Non Small Cell Lung Cancer
What this study did
NCT04989283 · National Cancer Institute (NCI)
2021-09-09 – 2031-05-10 · Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
What this study did
NCT07661173 · Anhui Provincial Cancer Hospital
2026-06-06 – 2031-05-06 · Non Small Cell Lung Cancer
What this study did
NCT07771764 · First Affiliated Hospital of Fujian Medical University
2026-08-01 – 2030-12-01 · ALK-positive Non Small Cell Lung Cancer
What this study did
NCT06109402 · Shanghai Pulmonary Hospital, Shanghai, China
2023-12-20 – 2030-11-01 · Stage II-IIIB(N2) Non-small Cell Lung Cancer
What this study did
NCT07680764 · Bristol-Myers Squibb
2026-09-10 – 2030-09-15 · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT07020065 · Swiss Cancer Institute
2026-04-10 – 2030-09 · Metastatic NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT07885709 · Peking University People's Hospital
2026-11-01 – 2030-08-01 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT07709585 · Guangzhou University of Traditional Chinese Medicine
2026-11-30 – 2030-07-31 · Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 Mutation, EGFR Exon 21 L858R Mutation
What this study did
NCT05891080 · Shanghai Pulmonary Hospital, Shanghai, China
2023-07-01 – 2030-07-01 · Stage III Non-small Cell Lung Cancer
What this study did
NCT07775040 · Sichuan Cancer Hospital and Research Institute
2026-08-24 – 2030-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT07229339 · Jonsson Comprehensive Cancer Center
2027-06-01 – 2030-06-01 · Lung Non-Squamous Non-Small Cell Carcinoma
What this study did
NCT05061550 · AstraZeneca
2022-04-14 – 2030-05-28 · Non-small Cell Lung Cancer
What this study did
NCT07122687 · Innovent Biologics (Suzhou) Co. Ltd.
2025-08-26 – 2030-04-30 · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT06745882 · H. Lee Moffitt Cancer Center and Research Institute
2025-06-13 – 2030-01 · Non-small Cell Lung Cancer
What this study did
NCT03872661 · Sun Yat-sen University
2019-03-01 – 2029-12-31 · Lung Cancer Stage III
What this study did
NCT05430802 · Tang-Du Hospital
2023-01-10 – 2029-12-01 · Non-small Cell Lung Cancer
What this study did
NCT04892953 · M.D. Anderson Cancer Center
2021-07-07 – 2029-09-30 · Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
What this study did
NCT05633667 · Gilead Sciences
2023-03-16 – 2029-09 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT05800587 · Fox Chase Cancer Center
2023-02-22 – 2029-08-01 · Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
What this study did
NCT07946848 · Immuneering Corporation
2026-12 – 2029-07 · NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell Cancer, Locally Advanced Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)
What this study did
NCT05364645 · SWOG Cancer Research Network
2022-07-25 – 2029-05-01 · Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT07405190 · Massachusetts General Hospital
2026-05-01 – 2029-03-01 · Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell, Lung Cancer Non Small Cell, Genomic Alterations
What this study did
NCT07624487 · Taipei Medical University Hospital
2026-06-09 – 2028-12-31 · Lung Adenocarcinoma Metastatic
What this study did
NCT06672068 · TYK Medicines, Inc
2025-02-20 – 2028-12-01 · NSCLC
What this study did
NCT06861218 · Zhejiang Cancer Hospital
2025-04 – 2028-12 · Leptomeningeal Metastases
What this study did
NCT07181499 · Betta Pharmaceuticals Co., Ltd.
2025-09 – 2028-12 · NSCLC, Adjuvant Drug Therapy, EGFR
What this study did
NCT06475300 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-06-25 – 2028-12 · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
What this study did
NCT05200481 · Intergroupe Francophone de Cancerologie Thoracique
2022-05-18 – 2028-10 · Non Small Cell Lung Cancer, ALK Gene Mutation
What this study did
NCT05011487 · Sun Yat-sen University
2021-08-13 – 2028-09 · Non-Small Cell Lung Cancer
What this study did
NCT05498428 · Janssen Research & Development, LLC
2022-11-11 – 2028-08-18 · Carcinoma, Non-small-Cell Lung
What this study did
NCT06142617 · Peking Union Medical College Hospital
2023-12-01 – 2028-06-30 · Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
What this study did
NCT06268210 · Yonsei University
2022-02-07 – 2028-06 · Non-small Cell Lung Cancer
What this study did
NCT06969027 · Shanghai Junshi Bioscience Co., Ltd.
2025-06-19 – 2028-05-31 · Non-small Cell Lung Cancer
What this study did
NCT06868836 · Shanghai Junshi Bioscience Co., Ltd.
2025-03-30 – 2028-04-04 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT07586202 · Janssen Research & Development, LLC
2026-07-28 – 2028-04-03 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06688656 · Shanghai Chest Hospital
2025-03-31 – 2028-03-31 · Lung Cancer
What this study did
NCT07871214 · Bristol-Myers Squibb
2026-11-30 – 2028-03-15 · Early-Stage Non-Small Cell Lung Cancer
What this study did
NCT05334277 · Sun Yat-sen University
2022-05-06 – 2028-02-29 · Non-small Cell Lung Cancer
What this study did
Phase 1/2 (110)
Non-Small Cell Lung Cancer
NCT06694454 · National Cancer Institute (NCI)
2026-11-24 – 2034-12-31 · Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
What this study did
NCT04198766 · Inhibrx Biosciences, Inc
2019-12-10 – 2033-07 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT07739966 · Daiichi Sankyo
2026-10-13 – 2032-01-29 · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
What this study did
NCT04665206 · Vivace Therapeutics, Inc
2021-03-24 – 2030-03-02 · Solid Tumor, Adult, Mesothelioma, NSCLC, Pleural Mesothelioma, Non-Pleural Mesothelioma, Non Small Cell Lung Cancer, Epithelioid Hemangioendothelioma (EHE), Adenoma, Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Mesothelial
What this study did
NCT07472647 · Shanghai JMT-Bio Inc.
2026-02-28 – 2030-02-28 · Non-Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
NCT06706076 · BlossomHill Therapeutics
2025-01-09 – 2029-07-31 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07397338 · Revolution Medicines, Inc.
2026-01-30 – 2029-05 · Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
What this study did
NCT07551778 · BOE Technology Group Co., Ltd.
2026-08 – 2029-04 · NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC), GC/GEJC
What this study did
NCT06996782 · AstraZeneca
2025-11-24 – 2029-02-23 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT05098132 · Synthekine
2022-01-25 – 2029-01 · Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
What this study did
NCT07070440 · Dizal Pharmaceuticals
2025-07-16 – 2028-12 · Non Small Cell Lung Cancer
What this study did
NCT07846358 · Genfleet Therapeutics (Shanghai) Inc.
2026-11 – 2028-12 · RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06162221 · Revolution Medicines, Inc.
2024-01-18 – 2028-12 · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC
What this study did
NCT07020221 · Verastem, Inc.
2025-06-24 – 2028-12 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
What this study did
NCT05431270 · Phanes Therapeutics
2022-08-11 – 2028-08 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT07744529 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-05-28 – 2028-05-28 · Leptomeningeal Metastasis From Lung Cancer
What this study did
NCT06943820 · Akeso
2025-05-21 – 2028-05 · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma, Advanced Solid Tumors
What this study did
NCT05443126 · Ellipses Pharma
2022-09-30 – 2028-03 · NSCLC
What this study did
NCT04956640 · Eli Lilly and Company
2021-07-19 – 2027-04 · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms
What this study did
NCT05501665 · Vanderbilt-Ingram Cancer Center
2023-05-09 – 2027-02-01 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
What this study did
NCT05904379 · Akeso
2023-07-13 – 2027-01-31 · Advanced Non-small-cell Lung Cancer
What this study did
NCT04083599 · Genmab
2019-09-17 – 2027-01 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Ductal Adenocarcinoma (PDAC)
What this study did
NCT05180799 · BioAtla, Inc.
2022-08-03 – 2026-06-30 · NSCLC, Melanoma
What this study did
NCT05978401 · Guangzhou Gloria Biosciences Co., Ltd.
2023-08-10 – 2026-04-01 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06758557 · Huabo Biopharm Co., Ltd.
2024-01-31 – 2026-02-28 · Advanced NSCLC, Advanced Endometrial Cancer
What this study did
NCT06173505 · Xencor, Inc.
2023-12-27 – 2025-12-29 · Nonsquamous Non-small Cell Lung Cancer
What this study did
NCT03970746 · PDC*line Pharma SAS
2019-09-10 – 2025-12 · Non Small Cell Lung Cancer
What this study did
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03559049 · University of Michigan Rogel Cancer Center
2018-12-24 – 2025-05-01 · Stage IV Non-small Cell Lung Cancer
What this study did
NCT05636267 · Akeso
2023-02-10 – 2025-04-15 · NSCLC
What this study did
NCT03267316 · Cantargia AB
2017-09-19 – 2024-03-14 · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
What this study did
NCT04647344 · Akeso
2020-11-24 – 2023-12-31 · Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
What this study did
NCT03317496 · Pfizer
2017-12-21 – 2022-12-20 · Non-small Cell Lung Cancer, Urothelial Cancer
What this study did
NCT02439450 · Heat Biologics
2015-04-15 – 2022-11-04 · Non-small Cell Lung Cancer
What this study did
NCT04430933 · NextCure, Inc.
2021-12-06 – 2022-10-30 · Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
What this study did
NCT03138889 · Nektar Therapeutics
2017-06-09 – 2022-08-24 · Non-Small Cell Lung Cancer
What this study did
NCT03840915 · EMD Serono Research & Development Institute, Inc.
2019-04-02 – 2022-07-29 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03562871 · IO Biotech
2018-08-22 – 2022-04-12 · NSCLC
What this study did
NCT02039674 · Merck Sharp & Dohme LLC
2014-02-21 – 2021-10-18 · Non-small Cell Lung Carcinoma
What this study did
NCT01982955 · Merck KGaA, Darmstadt, Germany
2013-12-23 – 2021-10-14 · Non-small Cell Lung Cancer
What this study did
NCT03706287 · Sichuan Cancer Hospital and Research Institute
2018-12-06 – 2021-03-10 · Lung Cancer Metastatic
What this study did
NCT03636685 · Chinese Academy of Medical Sciences
2018-08-15 – 2020-08-14 · NSCLC, Adenocarcinoma, Squamous Cell Carcinoma
What this study did
NCT02574078 · Bristol-Myers Squibb
2015-11-23 – 2020-04-15 · Non-Small Cell Lung Cancer
What this study did
NCT02347917 · Sumitomo Pharma Co., Ltd.
2015-02 – 2018-05-31 · Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
What this study did
NCT02049060 · Armando Santoro, MD
2013-01 – 2017-12 · Malignant Pleural Mesothelioma, Nonsquamous Nonsmall Cell Neoplasm of Lung
What this study did
NCT00921310 · Washington University School of Medicine
2009-09 – 2016-04 · Carcinoma, Non-Small-Cell Lung
What this study did
Phase 1 (175)
Non-Small Cell Lung Cancer
NCT06607185 · Eli Lilly and Company
2024-10-21 – 2030-01 · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT07699757 · Haisco Pharmaceutical Group Co., Ltd.
2026-07 – 2029-11 · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
What this study did
NCT06917079 · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
2025-03-31 – 2029-09 · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
What this study did
NCT06835569 · Alterome Therapeutics, Inc.
2025-03-05 – 2029-08 · Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
What this study did
NCT07458347 · Kestrel Therapeutics, Inc.
2026-04-21 – 2029-04 · KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
What this study did
NCT06969612 · Peking University Cancer Hospital & Institute
2025-05-15 – 2028-05 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06839105 · Shanghai Junshi Bioscience Co., Ltd.
2025-02-21 – 2028-04-30 · Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
What this study did
NCT04077463 · Janssen Research & Development, LLC
2019-09-04 – 2028-03-27 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04328844 · iOnctura
2020-02-25 – 2028-03 · Solid Tumor, Adult, Non-Hodgkin Lymphoma, Adult, NSCLC, Myelofibrosis, Uveal Melanoma
What this study did
NCT02609776 · Janssen Research & Development, LLC
2016-05-24 – 2027-12-31 · Non-Small-Cell Lung Cancer
What this study did
NCT06663306 · Shanghai Chest Hospital
2024-12-09 – 2027-12-30 · Lung Cancer (NSCLC), Leptomeningeal Metastasis
What this study did
NCT06946927 · Jemincare
2025-06-06 – 2027-12 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06561685 · Eli Lilly and Company
2024-09-19 – 2027-10 · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
What this study did
NCT04837716 · M.D. Anderson Cancer Center
2021-03-18 – 2027-09-23 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT05504278 · Innovent Biologics (Suzhou) Co. Ltd.
2022-09-20 – 2027-07-31 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06883630 · RemeGen Co., Ltd.
2025-03-13 – 2027-07-31 · Non-Small Cell Lung Cancer
What this study did
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT06594874 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2024-10-31 – 2027-01-01 · Non-Small Cell Lung Cancer, Advanced Solid Tumors
What this study did
NCT06431685 · Sichuan University
2024-04-25 – 2026-12-31 · NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
What this study did
NCT05136846 · Ohio State University Comprehensive Cancer Center
2021-12-06 – 2026-12-31 · Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
What this study did
NCT06333951 · Amgen
2024-09-17 – 2026-11-30 · Thoracic Tumors, Non-small Cell Lung Cancer
What this study did
NCT06447662 · Pfizer
2024-06-27 – 2026-10-09 · Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT05117476 · Cullinan Therapeutics Inc.
2021-10-29 – 2026-06 · Advanced Solid Tumor, NSCLC
What this study did
NCT06704724 · Pfizer
2024-12-10 – 2026-05-12 · Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT05911308 · UNC Lineberger Comprehensive Cancer Center
2024-04-01 – 2025-02-27 · Non-Small Cell Lung Cancer
What this study did
NCT02922764 · Inspirna, Inc.
2016-11-01 – 2025-01-22 · Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
What this study did
NCT03509012 · AstraZeneca
2018-05-02 – 2025-01-08 · Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
What this study did
NCT03307785 · Tesaro, Inc.
2017-10-12 – 2024-12-11 · Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
What this study did
NCT03177291 · H. Lee Moffitt Cancer Center and Research Institute
2017-09-26 – 2024-12-04 · Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer, Squamous Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung
What this study did
NCT03846310 · Arcus Biosciences, Inc.
2019-04-01 – 2024-11-18 · Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
What this study did
NCT04287894 · The Netherlands Cancer Institute
2018-12-28 – 2024-11-04 · Stage III NSCLC
What this study did
NCT03396445 · Merck Sharp & Dohme LLC
2018-02-18 – 2024-09-27 · Pharmacokinetics, Solid Tumor, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms
What this study did
NCT02419495 · M.D. Anderson Cancer Center
2015-06-26 – 2024-09-16 · Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
What this study did
NCT05241873 · Blueprint Medicines Corporation
2022-03-04 – 2024-07-31 · Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q
What this study did
NCT05273814 · Tianjin Medical University Cancer Institute and Hospital
2022-08-01 – 2024-02-01 · Non-Small Cell Lung Cancer
What this study did
NCT04452214 · Cantargia AB
2020-09-24 – 2023-06-28 · Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT02120807 · Memorial Sloan Kettering Cancer Center
2014-04-15 – 2023-01-24 · Stage IV Lung Adenocarcinoma
What this study did
NCT05153408 · Blueprint Medicines Corporation
2022-01-13 – 2022-12-09 · Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
What this study did
NCT04022876 · Aileron Therapeutics, Inc.
2019-09-03 – 2022-08-30 · Non Small Cell Lung Cancer, Small-cell Lung Cancer
What this study did
NCT04861948 · Innovent Biologics (Suzhou) Co. Ltd.
2021-05-25 – 2022-07-30 · Solid Tumors, Lung Adenocarcinoma, Osteosarcoma
What this study did
NCT02535325 · National Cancer Institute (NCI)
2015-09-30 – 2022-06-14 · Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Adenocarcinoma AJCC v7, Stage IIIA Lung Large Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Adenocarcinoma AJCC v7, Stage IIIB Lung Large Cell Carcinoma AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Adenocarcinoma AJCC v7, Stage IV Lung Large Cell Carcinoma AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
What this study did
NCT03023319 · Nagla Abdel Karim
2019-12-10 – 2022-05-10 · Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer
What this study did
NCT04173338 · Augusta University
2020-01-23 – 2022-03-28 · Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
What this study did
NCT01655225 · Eli Lilly and Company
2012-07-31 – 2022-02-02 · Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
What this study did
NCT03498222 · Queen Mary University of London
2018-06-01 – 2021-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03790228 · Henan Cancer Hospital
2019-03-22 – 2021-08-31 · Non-squamous Cell Non-Small Cell Lung Cancer
What this study did
NCT03064854 · Novartis Pharmaceuticals
2017-05-24 – 2021-07-28 · Non-small Cell Lung Cancer
What this study did
Phase 4 (16)
Non-Small Cell Lung Cancer
NCT07092202 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-04-15 – 2027-11-01 · Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor
What this study did
NCT06357598 · The Affiliated Hospital of Qingdao University
2024-01-18 – 2025-12-31 · Non-small-cell Lung Cancer (NSCLC)
What this study did
NCT03656549 · Radboud University Medical Center
2019-02-01 – 2023-12-29 · Non Small Cell Lung Cancer, Mesothelioma
What this study did
NCT03655834 · Radboud University Medical Center
2019-02-01 – 2021-08-01 · Non Small Cell Lung Cancer, Mesothelioma
What this study did
NCT03655821 · Radboud University Medical Center
2019-02-01 – 2021-05-11 · Non Small Cell Lung Cancer, Mesothelioma
What this study did
NCT03768037 · Guangdong Association of Clinical Trials
2018-11-26 – 2020-11-26 · Advanced Non-squamous NSCLC
What this study did
NCT03607149 · Centre Georges Francois Leclerc
2017-04-06 – 2020-02-20 · Non-small Cell Lung Cancer
What this study did
NCT02399566 · Hunan Province Tumor Hospital
2015-05 – 2019-01 · Lung Adenocarcinoma
What this study did
NCT03460678 · Hikma Pharmaceuticals LLC
2018-02-28 – 2018-11-14 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02031601 · Qilu Hospital of Shandong University
2014-01 – 2017-12 · Non-Small-Cell Lung Cancer
What this study did
NCT01020786 · Eli Lilly and Company
2009-11 – 2012-06 · Non Small Cell Lung Cancer
What this study did
NCT00380718 · Eli Lilly and Company
2006-11 – 2009-11 · Non-small Cell Lung Cancer
What this study did
NCT01442909 · Taipei Veterans General Hospital, Taiwan
2008-03 – 2009-09 · Non-small-cell Lung Cancer
What this study did
Other / comorbidity
NCT06824792 · NING LI
2025-03-01 – 2030-02-28 · Advanced Solid Tumors
What this study did
NCT01143974 · Chinese Academy of Medical Sciences
2010-06 – 2012-06 · Locally Advanced Malignant Neoplasm
What this study did
Early phase / not applicable (22)
Non-Small Cell Lung Cancer
NCT07873086 · Peking University People's Hospital
2026-11-01 – 2033-10-01 · Non-Small Cell Lung Cancer
What this study did
NCT07538193 · Tang-Du Hospital
2026-05 – 2029-12 · Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
What this study did
NCT02194738 · National Cancer Institute (NCI)
2014-09-26 – 2027-09-21 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT06576635 · University of Illinois at Chicago
2024-12-16 – 2026-09 · NSCLC
What this study did
NCT05527808 · Jun Liu
2022-08-01 – 2025-12-30 · Lung Adenocarcinoma
What this study did
NCT06643000 · Henan Cancer Hospital
2024-12-20 – 2025-05-30 · Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
What this study did
NCT04970043 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2021-07-31 – 2024-07-30 · Lung Cancer Stage II
What this study did
NCT03671538 · Lingyu Luo
2018-10-01 – 2020-08-31 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT03489616 · Shandong Cancer Hospital and Institute
2018-01-15 – 2019-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02951897 · Third Military Medical University
2016-04 – 2019-12 · Lung Adenocarcinoma, Stage I, Diagnoses Diseases, Circulating Tumor Cells, Treatment
What this study did
NCT03566576 · Fujian Cancer Hospital
2018-07-01 – 2018-10-01 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT02274038 · University of Pennsylvania
2015-03 – 2018-07 · Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
What this study did
NCT02145078 · Barbara Ann Karmanos Cancer Institute
2014-06 – 2017-03-07 · Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT02679443 · Post Graduate Institute of Medical Education and Research, Chandigarh
2015-07 – 2016-12 · Lung Adenocarcinoma, Neutropenia, Anemia, Thrombocytopenia, Nonsquamous Nonsmall Cell Neoplasm of Lung
What this study did
NCT01063283 · University of Chicago
2010-03 – 2016-06 · Advanced Non-squamous Non-Small Cell Lung Cancer
What this study did
NCT02148380 · Baohui Han
2014-05 – 2015-12 · Non-Small-Cell Lung Cancer
What this study did
NCT01860508 · Fudan University
2013-02 – 2014-02 · Non-small Cell Lung Cancer
What this study did
NCT01209520 · University of Miami
2009-07 – 2013-12 · Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
What this study did
NCT00903292 · National Cheng-Kung University Hospital
2009-03 – 2010-12 · Non-Small Cell Lung Cancer
What this study did
NCT01004601 · Chang Gung Memorial Hospital
2005-03 – 2008-10 · Non Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05305885 · The First Hospital of Jilin University
2022-08-19 – 2024-07 · Leptomeningeal Metastasis
What this study did
Used as active comparator (115)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (79)
Non-Small Cell Lung Cancer
NCT06899126 · Daiichi Sankyo
2025-10-24 – 2032-11-24 · Non-small Cell Lung Cancer
What this study did
NCT07190248 · Merck Sharp & Dohme LLC
2025-10-08 – 2032-08-06 · Non-small Cell Lung Cancer
What this study did
NCT07896005 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-12 – 2032-03 · Non Small Cell Lung Cancer
What this study did
NCT03456076 · Hoffmann-La Roche
2018-08-16 – 2031-11-19 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07754123 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2026-10-23 – 2031-07-31 · Advanced or Metastatic NSCLC
What this study did
NCT05555732 · Daiichi Sankyo
2023-01-11 – 2031-05-11 · Metastatic Non Small Cell Lung Cancer
What this study did
NCT07833202 · Shanghai Jeyou Pharmaceutical Co., Ltd.
2026-10 – 2030-09 · NSCLC
What this study did
NCT07174908 · InxMed (Shanghai) Co., Ltd.
2025-09-10 – 2030-09 · Non-Small Cell Lung Cancer
What this study did
NCT06416410 · Allist Pharmaceuticals, Inc.
2024-08-07 – 2030-08 · Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
What this study did
NCT06281964 · Avistone Biotechnology Co., Ltd.
2023-12-01 – 2030-06-30 · Non-Small-Cell Lung Cancer
What this study did
NCT04194944 · Eli Lilly and Company
2020-02-17 – 2030-06 · Non-Small Cell Lung Cancer
What this study did
NCT06074588 · Merck Sharp & Dohme LLC
2023-11-12 – 2030-03-11 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT07948408 · Wayshine Biopharm, Inc.
2026-12-10 – 2029-10-31 · Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT07376382 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-01 – 2029-06-06 · NSCLC
What this study did
NCT07633873 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-06-02 – 2029-05-30 · Non-Small Cell Lung Cancer
What this study did
NCT06970782 · Avistone Biotechnology Co., Ltd.
2025-05-15 – 2028-12-31 · Non-Small-Cell Lung Cancer
What this study did
NCT07109531 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
2025-08-04 – 2028-12-31 · Locally Advanced or Metastatic NSCLC
What this study did
NCT06711900 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-10-30 – 2028-12 · Non-Small Cell Lung Cancer
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
NCT06956001 · Allist Pharmaceuticals, Inc.
2024-11-19 – 2028-07 · EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06151574 · Boehringer Ingelheim
2024-02-09 – 2028-01-28 · Lung Cancer, Non-squamous, Non-small Cell
What this study did
NCT07178795 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-09-29 – 2027-12 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT05668988 · Dizal Pharmaceuticals
2022-12-13 – 2027-10-31 · Non-small Cell Lung Cancer
What this study did
NCT05048797 · AstraZeneca
2021-10-28 – 2027-07-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT06430437 · Jiangsu HengRui Medicine Co., Ltd.
2024-07-29 – 2027-04 · Non-Small Cell Lung Cancer With HER2- Mutations
What this study did
NCT05767892 · Suzhou Puhe Pharmaceutical Technology Co., LTD
2023-05-01 – 2026-12-31 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT02453282 · AstraZeneca
2015-07-21 – 2026-12-31 · Non-Small-Cell Lung Carcinoma NSCLC
What this study did
NCT02542293 · AstraZeneca
2015-11-03 – 2026-12-31 · Non Small Cell Lung Carcinoma NSCLC
What this study did
NCT05261399 · AstraZeneca
2022-08-03 – 2026-11-23 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05870319 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2023-06-26 – 2026-09-30 · Non-small Cell Lung Cancer
What this study did
NCT04129502 · Takeda
2020-01-10 – 2026-09-22 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT06927986 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-03-30 – 2026-08-30 · EGFR-mutated Locally Advanced or Metastatic NSCLC
What this study did
NCT03003962 · AstraZeneca
2017-01-02 – 2026-06-30 · Non Small Cell Lung Carcinoma NSCLC
What this study did
NCT05015608 · Hutchison Medipharma Limited
2021-11-22 – 2025-08-22 · Non-small Cell Lung Cancer
What this study did
NCT03088540 · Regeneron Pharmaceuticals
2017-05-29 – 2025-04-18 · Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
What this study did
NCT06110663 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2023-12-30 – 2025-02-28 · Non-Small Cell Lung Cancer
What this study did
NCT04222972 · Hoffmann-La Roche
2020-07-24 – 2025-01-27 · RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue
What this study did
NCT01656551 · National Cancer Institute, Naples
2012-08 – 2024-11 · Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
What this study did
NCT03991403 · Samsung Medical Center
2019-08-27 – 2024-03-11 · Non-small Cell Lung Cancer
What this study did
NCT02576574 · EMD Serono Research & Development Institute, Inc.
2015-10-29 – 2024-01-29 · First Line Non-Small Cell Lung Cancer
What this study did
NCT01828099 · Novartis Pharmaceuticals
2013-07-09 – 2024-01-07 · Non-Small Cell Lung Cancer
What this study did
Phase 2/3 (6)
Non-Small Cell Lung Cancer
NCT07642024 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-07-24 – 2032-12 · Non-small Cell Lung Cancer
What this study did
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT01481259 · People's Hospital of Guangxi Zhuang Autonomous Region
2010-01 – 2013-07 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT02777788 · Shanghai University of Traditional Chinese Medicine
2014-09 – 2019-12 · Cancer
What this study did
Phase 2 (26)
Non-Small Cell Lung Cancer
NCT07001618 · Gustave Roussy, Cancer Campus, Grand Paris
2025-11-17 – 2032-09 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07256509 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2025-11-30 – 2032-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT06731907 · Merck Sharp & Dohme LLC
2025-03-30 – 2032-03-12 · Non-small Cell Lung Cancer
What this study did
NCT07863167 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-10-30 – 2030-12-30 · Non-small Cell Lung Cancer
What this study did
NCT07365410 · Tianjin Medical University Cancer Institute and Hospital
2026-01 – 2028-12 · Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
What this study did
NCT07420439 · Intergroupe Francophone de Cancerologie Thoracique
2026-09-15 – 2028-11-15 · Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)
What this study did
NCT04736173 · Arcus Biosciences, Inc.
2021-02-08 – 2026-09-17 · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
What this study did
NCT04455594 · The First Affiliated Hospital of Guangzhou Medical University
2020-10 – 2025-10 · Non-Small Cell Lung Cancer Stage IIIA
What this study did
NCT03971474 · SWOG Cancer Research Network
2019-05-28 – 2024-01-01 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT02117167 · UNICANCER
2014-04-23 – 2023-12 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT03777124 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-11 – 2023-06-29 · NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody, Chemotherapy Effect
What this study did
NCT02631460 · Sun Yat-sen University
2015-12 – 2019-12 · NSCLC
What this study did
NCT02669719 · Shanghai Chest Hospital
2016-01 – 2019-01 · Non Small Cell Lung Cancer
What this study did
NCT02117024 · Heat Biologics
2014-07 – 2018-04 · Non Small Cell Lung Cancer
What this study did
NCT02488694 · AIO-Studien-gGmbH
2015-11 – 2017-12 · Non-small-cell Lung Cancer With Somatic EGFR Mutations
What this study did
NCT02407366 · People's Hospital of Guangxi Zhuang Autonomous Region
2014-12 – 2017-12 · Non-small Cell Lung Cancer
What this study did
NCT02919462 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
2016-03 – 2017-05 · Carcinoma, Non-Small-Cell Lung, Secondary, Advanced Stage IIIB, High Thymidylate Synthase Expression
What this study did
NCT01395758 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
2011-07 – 2016-08 · Metastatic Non-Small Cell Lung Cancer
What this study did
NCT01646125 · Novartis Pharmaceuticals
2012-11-23 – 2015-11-04 · Advanced Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT01204307 · Chang Gung Memorial Hospital
2010-01 – 2015-06 · Advanced Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT01401192 · Samsung Medical Center
2011-07 – 2013-12 · Non-small Cell Lung Cancer
What this study did
NCT01471197 · Bristol-Myers Squibb
2012-07 – 2013-02 · Lung Cancer - Non Small Cell
What this study did
NCT00550173 · Eli Lilly and Company
2007-11 – 2012-01 · Non-Small-Cell Lung Cancer
What this study did
NCT00372788 · AstraZeneca
2006-08 – 2008-12 · Non-small Cell Lung Cancer
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
NCT00768755 · Pfizer
2009-01 – 2012-03 · Carcinoma, Non-Small Cell Lung
What this study did
Phase 1 (1)
Other / comorbidity
NCT06384352 · MediLink Therapeutics (Suzhou) Co., Ltd.
2024-05-01 – 2031-06-30 · Advanced Solid Tumors
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT05689671 · Nikolaj Frost MD
2023-12-06 – 2026-10 · Non-Small Cell Lung Cancer Metastatic
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT04552613 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2020-11-23 – 2023-09-24 · Non-small-lung-cell Cancer, NSCLC, EGFR Gene Mutation
What this study did
Appears in other studies (91)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (37)
Non-Small Cell Lung Cancer
NCT06623422 · Merck Sharp & Dohme LLC
2024-10-21 – 2038-01-26 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT05624996 · NRG Oncology
2023-07-12 – 2036-10-15 · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
What this study did
NCT07777822 · Revolution Medicines, Inc.
2026-08-14 – 2031-02 · NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT06119581 · Eli Lilly and Company
2023-12-21 – 2031-01 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
What this study did
NCT07050043 · Dr Arvindran A/L Alaga
2025-05-19 – 2030-12-31 · NSCLC (Non-small Cell Lung Carcinoma), First Line Therapy, Locally Advanced/Metastatic NSCLC
What this study did
NCT05487391 · Qilu Pharmaceutical Co., Ltd.
2022-12-08 – 2029-05-22 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01993810 · Radiation Therapy Oncology Group
2014-01-03 – 2028-11-30 · Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
What this study did
NCT05116462 · Innovent Biologics (Suzhou) Co. Ltd.
2024-03-15 – 2028-10-14 · Non-Small Cell Lung Cancer
What this study did
NCT03800134 · AstraZeneca
2018-12-06 – 2028-09-11 · Non-Small Cell Lung Cancer
What this study did
NCT04339218 · Institut Bergonié
2020-08-28 – 2028-08-27 · Lung Adenocarcinoma, Cryotherapy Effect
What this study did
NCT06382116 · Sichuan Baili Pharmaceutical Co., Ltd.
2024-05-22 – 2027-12 · Non-small Cell Lung Cancer
What this study did
NCT04765059 · AstraZeneca
2021-09-12 – 2027-06-02 · Non-small Cell Lung Cancer
What this study did
NCT04379635 · BeiGene
2020-05-29 – 2027-03-31 · Non Small Cell Lung Cancer
What this study did
NCT04768075 · Guangdong Association of Clinical Trials
2021-05-28 – 2026-04-30 · Non-Small-Cell Lung Cancer
What this study did
NCT03519971 · AstraZeneca
2018-03-29 – 2026-03-09 · Non-Small Cell Lung Cancer
What this study did
NCT04203511 · Incyte Corporation
2020-07-31 – 2025-01-31 · Non-small Cell Lung Cancer
What this study did
NCT05132413 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2021-12-30 – 2024-12-30 · Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
What this study did
NCT02974426 · Shanghai Chest Hospital
2016-11 – 2024-02 · Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
What this study did
NCT03912389 · Biocad
2019-06-01 – 2023-12 · Non-Squamous Non-Small Cell Neoplasm of Lung
What this study did
NCT03607539 · Innovent Biologics (Suzhou) Co. Ltd.
2018-08-23 – 2022-05-31 · Lung Neoplasms
What this study did
NCT04439890 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-08-08 – 2021-12-31 · Advanced Non-squamous Cell Non-small Cell Lung Cancer
What this study did
NCT02518802 · Tang-Du Hospital
2015-01 – 2020-01 · Lung Neoplasms
What this study did
NCT01544179 · AstraZeneca
2012-03-15 – 2019-11-20 · Non-Small Cell Lung Cancer
What this study did
NCT03269162 · lihegen
2016-09-30 – 2019-09-30 · NSCLC
What this study did
NCT01041781 · Alliance for Clinical Trials in Oncology
2010-02 – 2018-03 · Lung Cancer
What this study did
NCT02900742 · Shanghai University of Traditional Chinese Medicine
2013-03 – 2017-06-01 · Cancer
What this study did
NCT01836575 · Instituto Nacional de Cancer, Brazil
2008-04 – 2012-12 · Non Small Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT04158141 · NRG Oncology
2020-01-29 – 2023-11-20 · Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
What this study did
Phase 2/3 (3)
Non-Small Cell Lung Cancer
NCT07365319 · Eikon Therapeutics
2026-06-15 – 2040-12-31 · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
What this study did
Other / comorbidity
NCT01907100 · Boehringer Ingelheim
2013-09-19 – 2018-08-31 · Mesothelioma
What this study did
Phase 2 (40)
Non-Small Cell Lung Cancer
NCT07098988 · CatalYm GmbH
2025-08-01 – 2031-03-31 · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
What this study did
NCT07822984 · Fudan University
2026-10 – 2030-09 · EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT03137771 · NRG Oncology
2017-04-07 – 2028-12 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT04846634 · Tianjin Medical University Cancer Institute and Hospital
2021-08 – 2028-02 · Resectable Locally Advanced Non-small Cell Lung Cancer
What this study did
NCT04105270 · Masonic Cancer Center, University of Minnesota
2022-11-30 – 2028-01 · Adenocarcinoma of Lung, Lung Cancer
What this study did
NCT05003037 · Li Zhang, MD
2022-01-06 – 2027-11-03 · Non Small Cell Lung Cancer
What this study did
NCT06194448 · AstraZeneca
2024-04-21 – 2027-07-07 · Lung Cancer
What this study did
NCT06897046 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-07-30 – 2027-05-25 · Non-small Cell Lung Cancer (NSCLC), II-IIIB
What this study did
NCT05766800 · Shanghai Pulmonary Hospital, Shanghai, China
2023-03-14 – 2027-04-01 · Locally Advanced, Non-small Cell Lung Cancer
What this study did
NCT06132698 · West China Hospital
2023-11-30 – 2026-06-30 · NSCLC Associated With Leptomeningeal Metastases
What this study did
NCT05403385 · iTeos Therapeutics
2022-08-26 – 2025-10 · Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
What this study did
NCT04765709 · Mario Negri Institute for Pharmacological Research
2021-09-24 – 2025-01-30 · Non-small Cell Lung Cancer Stage III
What this study did
NCT05014815 · BeiGene
2021-11-16 – 2024-09-04 · Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
What this study did
NCT05611879 · Beijing Tsinghua Chang Gung Hospital
2023-03-12 – 2024-04-30 · NSCLC, Stage III
What this study did
NCT04470076 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-07-10 – 2023-07-30 · Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy, EGFR TKI
What this study did
NCT04846452 · The First Affiliated Hospital with Nanjing Medical University
2021-06-01 – 2023-05-01 · Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer
What this study did
NCT04586465 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-10-10 – 2022-06-30 · Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, PET/CT
What this study did
NCT04265534 · Calithera Biosciences, Inc
2020-07-24 – 2022-02-09 · Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
What this study did
NCT02977169 · Shanghai Chest Hospital
2016-11 – 2021-12 · Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
What this study did
NCT02940990 · Shanghai Chest Hospital
2016-11 – 2019-12 · NSCLC, SBRT, GM-CSF
What this study did
NCT02930954 · Caicun Zhou
2016-11 – 2018-12 · Non-small-cell Lung Cancer
What this study did
NCT00950365 · Albert Einstein College of Medicine
2006-04 – 2017-11-17 · Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT03050437 · Samsung Medical Center
2013-03 – 2017-03 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02119650 · Incyte Corporation
2014-02-11 – 2016-06-21 · NSCLC (Non-small Cell Lung Carcinoma)
What this study did
NCT01784549 · IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
2012-07 – 2015-12 · Non Small Cell Lung Cancer
What this study did
NCT00824408 · Boehringer Ingelheim
2009-03 – 2015-08 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00771953 · University of Maryland, Baltimore
2008-11 – 2014-12 · Lung Cancer, Non Small Cell Lung Cancer
What this study did
NCT00745875 · AstraZeneca
2008-08 – 2010-01 · Non Small Cell Lung Cancer, Lung Cancer
What this study did
NCT00111839 · EMD Serono
2005-05-31 – 2009-03-31 · Lung Cancer, Non Small Cell Lung Carcinoma
What this study did
NCT00530621 · Eli Lilly and Company
2007-09 – 2008-10 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT00715611 · Memorial Sloan Kettering Cancer Center
2008-10-11 – 2027-07 · Mesothelioma
What this study did
NCT03875144 · Institut du Cancer de Montpellier - Val d'Aurelle
2020-09-10 – 2027-06 · Peritoneal Mesothelioma, Peritoneal Carcinomatosis
What this study did
NCT00334594 · Swiss Cancer Institute
2005-11-14 – 2018-01-23 · Malignant Mesothelioma
What this study did
Phase 1/2 (5)
Non-Small Cell Lung Cancer
NCT06253871 · Iambic Therapeutics, Inc
2024-03-25 – 2028-12 · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
What this study did
Other / comorbidity
NCT05932199 · Baylor College of Medicine
2024-07-03 – 2028-05-31 · Mesothelioma
What this study did
NCT01064648 · National Cancer Institute (NCI)
2010-03-15 – 2027-03-31 · Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
What this study did
NCT02879669 · Targovax Oy
2016-06 – 2020-05 · To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
What this study did
Phase 1 (1)
Other / comorbidity
NCT03628521 · Shanghai Chest Hospital
2018-07-20 – 2020-12-31 · Lung Cancer, Advanced Stage
What this study did
Phase 4 (2)
Non-Small Cell Lung Cancer
NCT07279935 · AstraZeneca
2026-05-26 – 2030-05-18 · Non-small Cell Lung Cancer
What this study did
NCT02804646 · Anhui Provincial Hospital
2016-06 – 2018-12 · Adenocarcinoma of Lung
What this study did
Early phase / not applicable (3)
Non-Small Cell Lung Cancer
NCT06484491 · University Medical Center Groningen
2025-09-01 – 2028-10-01 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07751536 · Shuanghu Yuan
2026-08-05 – 2028-07-31 · Leptomeningeal Metastasis From Lung Cancer
What this study did
Other / comorbidity
NCT06649448 · Shandong Cancer Hospital and Institute
2024-10-10 – 2026-05-31 · Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
What this study did

Competitive landscape

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pemetrexed (Alimta): this drugApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 550 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(178 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Alimta (pemetrexed) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (22)
November 2026 (4)
Phase 1/2Leptomeningeal MetastasisActive not recruiting
Est. primary completion 2026-11 · NCT06462222 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-11 · NCT06704620 · CT.gov ↗
What to watch
Phase 2Chordomas, ChordomaRecruiting
Est. primary completion 2026-11-30 · NCT06794645 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-30 · NCT07122687 · CT.gov ↗
What to watch
December 2026 (18)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06943820 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12 · NCT06890182 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05456256 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT03786692 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06246110 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06754644 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT04585490 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4, Solid TumorsActive not recruiting
Est. primary completion 2026-12-01 · NCT06809530 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-24 · NCT06783647 · CT.gov ↗
What to watch
Phase 2DLBCLActive not recruiting
Est. primary completion 2026-12-28 · NCT05253118 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumor CancerRecruiting
Est. primary completion 2026-12-30 · NCT07381829 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05136846 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT02609776 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06440954 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT04136535 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05805631 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05059522 · CT.gov ↗
What to watch
2027 (58)
January 2027 (5)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-01 · NCT06741644 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-01-01 · NCT06971406 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-11 · NCT06417814 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal MetastasesRecruiting
Est. primary completion 2027-01-15 · NCT06462092 · CT.gov ↗
What to watch
Phase 2Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation …Active not recruiting
Est. primary completion 2027-01-31 · NCT03744793 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1Mesotheliomas PleuralRecruiting
Est. primary completion 2027-02-01 · NCT03760575 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-05 · NCT06946797 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-12 · NCT04077463 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03 · NCT05443126 · CT.gov ↗
What to watch
Phase 1NeoplasmsActive not recruiting
Est. primary completion 2027-03-01 · NCT02817633 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04 · NCT04956640 · CT.gov ↗
What to watch
Phase 1/2KRAS P.G12CRecruiting
Est. primary completion 2027-04 · NCT05410145 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-27 · NCT06364917 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT06944470 · CT.gov ↗
What to watch
May 2027 (5)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT06969612 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT04410796 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer, Lung CancerRecruiting
Est. primary completion 2027-05-01 · NCT05358548 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-01 · NCT07092202 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch
June 2027 (9)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT07070440 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06162221 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06475300 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06514027 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-30 · NCT07845916 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT05198830 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2027-06-30 · NCT05112965 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06448754 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-31 · NCT06784791 · CT.gov ↗
What to watch
August 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT06917079 · CT.gov ↗
What to watch
Phase 2Peritoneal Malignant MesotheliomaRecruiting
Est. primary completion 2027-08-01 · NCT05001880 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-12 · NCT07486817 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-17 · NCT05498428 · CT.gov ↗
What to watch
September 2027 (5)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-23 · NCT04837716 · CT.gov ↗
What to watch
Phase 1Advanced MalignanciesActive not recruiting
Est. primary completion 2027-09-30 · NCT03233139 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Metastatic CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT05335941 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT03793179 · CT.gov ↗
What to watch
October 2027 (6)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10 · NCT06561685 · CT.gov ↗
What to watch
Phase 1/2Malignant Pleural MesotheliomaRecruiting
Est. primary completion 2027-10 · NCT05765084 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-15 · NCT05012254 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-20 · NCT05118854 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-31 · NCT07309952 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT07154368 · CT.gov ↗
What to watch
November 2027 (6)
Phase 1Malignant Pleural MesotheliomaActive not recruiting
Est. primary completion 2027-11 · NCT04162015 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06772623 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06901817 · CT.gov ↗
What to watch
Phase 2Sarcoma,Soft TissueRecruiting
Est. primary completion 2027-11-01 · NCT04605770 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-30 · NCT04297605 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT06142617 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07846358 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT06672068 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-30 · NCT06663306 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal MetastasisRecruiting
Est. primary completion 2027-12-30 · NCT06762080 · CT.gov ↗
What to watch
Phase 1Malignant TumorsRecruiting
Est. primary completion 2027-12-31 · NCT07004244 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06969027 · CT.gov ↗
What to watch
2028 (36)
February 2028 (3)
Phase 2Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory CancerRecruiting
Est. primary completion 2028-02 · NCT05681195 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-02-16 · NCT07415031 · CT.gov ↗
What to watch
Phase 4Advanced Solid TumorsNot yet recruiting
Est. primary completion 2028-02-29 · NCT06824792 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-01 · NCT07405190 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-02 · NCT07586202 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-03-15 · NCT07871214 · CT.gov ↗
What to watch
April 2028 (5)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07458347 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07551778 · CT.gov ↗
What to watch
Phase 2Leptomeningeal MetastasisNot yet recruiting
Est. primary completion 2028-04-01 · NCT06441045 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04-10 · NCT07383116 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04-30 · NCT06839105 · CT.gov ↗
What to watch
May 2028 (5)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2028-05 · NCT07128303 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-05 · NCT06861218 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-05 · NCT06268210 · CT.gov ↗
What to watch
Phase 2Pleural MesotheliomasRecruiting
Est. primary completion 2028-05 · NCT07234058 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-28 · NCT07744529 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-06 · NCT05502237 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07915037 · CT.gov ↗
What to watch
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-01 · NCT05800587 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
September 2028 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT07020065 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09-15 · NCT07680764 · CT.gov ↗
What to watch
Phase 2Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant MesotheliomaRecruiting
Est. primary completion 2028-09-21 · NCT06057935 · CT.gov ↗
What to watch
Phase 2Malignant Neoplam, Advanced Solid TumorsRecruiting
Est. primary completion 2028-09-26 · NCT07793942 · CT.gov ↗
What to watch
October 2028 (3)
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10 · NCT06335355 · CT.gov ↗
What to watch
Phase 2MedulloblastomaActive not recruiting
Est. primary completion 2028-10-13 · NCT01878617 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-31 · NCT07131319 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11 · NCT07181499 · CT.gov ↗
What to watch
Phase 3Unresectable Pleural MesotheliomaActive not recruiting
Est. primary completion 2028-11-16 · NCT06097728 · CT.gov ↗
What to watch
December 2028 (5)
Phase 1Ewing Sarcoma, Colorectal AdenocarcinomaRecruiting
Est. primary completion 2028-12 · NCT03715933 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-12-31 · NCT05382559 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07624487 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT04092283 · CT.gov ↗
What to watch
2029 (28)
January 2029 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01 · NCT05098132 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01 · NCT06712316 · CT.gov ↗
What to watch
Phase 3Metastatic Non-squamous Lung CancerRecruiting
Est. primary completion 2029-01 · NCT05692999 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07885709 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-31 · NCT06706076 · CT.gov ↗
What to watch
February 2029 (3)
Phase 1/2Locally Advanced / Metastatic Solid TumorsRecruiting
Est. primary completion 2029-02 · NCT07335497 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-23 · NCT06996782 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-02-28 · NCT07472647 · CT.gov ↗
What to watch
March 2029 (2)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-03 · NCT06970639 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-03-06 · NCT07661173 · CT.gov ↗
What to watch
April 2029 (4)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07699757 · CT.gov ↗
What to watch
Phase 1Large B-cell Lymphoma, Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2029-04 · NCT07608731 · CT.gov ↗
What to watch
Phase 2MesotheliomaNot yet recruiting
Est. primary completion 2029-04 · NCT07514793 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch
May 2029 (6)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT06835569 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07946848 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07538193 · CT.gov ↗
What to watch
Phase 2Metastatic Bladder Urothelial Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Bladder Cancer AJCC v8, MTAP DeletionRecruiting
Est. primary completion 2029-05-10 · NCT06630416 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05-23 · NCT06667076 · CT.gov ↗
What to watch
June 2029 (2)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-06 · NCT06474455 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06-01 · NCT07229339 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-09 · NCT05633667 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT04892953 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-02 · NCT04665206 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07771764 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-31 · NCT03872661 · CT.gov ↗
What to watch
2030 (20)
January 2030 (5)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01 · NCT06607185 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT06745882 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01-16 · NCT05800015 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-24 · NCT07662395 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-31 · NCT04267848 · CT.gov ↗
What to watch
February 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-02-25 · NCT05067283 · CT.gov ↗
What to watch
April 2030 (1)
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
May 2030 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-05-31 · NCT07822542 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-06-30 · NCT07775040 · CT.gov ↗
What to watch
July 2030 (3)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-31 · NCT07739966 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-31 · NCT07709585 · CT.gov ↗
What to watch
October 2030 (1)
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-10-10 · NCT07873086 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-11-01 · NCT06109402 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-18 · NCT06627647 · CT.gov ↗
What to watch
December 2030 (4)
Phase 1/2Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma …Recruiting
Est. primary completion 2030-12-09 · NCT07594626 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07865910 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07897188 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07890493 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-01-31 · NCT07507188 · CT.gov ↗
What to watch
April 2031 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-04 · NCT07829549 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-12 · NCT07063745 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2031-10 · NCT06236438 · CT.gov ↗
What to watch
2032 (5)
January 2032 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-01 · NCT07234877 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-01-29 · NCT05789082 · CT.gov ↗
What to watch
February 2032 (3)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-02 · NCT07943325 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-02-13 · NCT04165070 · CT.gov ↗
What to watch
2033 (2)
July 2033 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch
November 2033 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2033-11-30 · NCT07877584 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2035-08-01 · NCT07720167 · CT.gov ↗
What to watch
2036 (1)
November 2036 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2036-11 · NCT07005102 · CT.gov ↗
What to watch
2039 (1)
April 2039 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2039-04-01 · NCT06096844 · CT.gov ↗
What to watch

See the full readout calendar ↗